Convalescent plasma in hospitalized pediatric and obstetric coronavirus disease 2019 (COVID-19) patients.

ABSTRACT:

Background

Published data on coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) use in children and obstetric patients are limited. We describe a single-center experience of hospitalized patients who received CCP for acute COVID-19.

Methods

A retrospective review of children 0-18-years-old and pregnant patients hospitalized with laboratory-confirmed acute COVID-19 who received CCP from March 1, 2020 to March 1, 2021 was performed. Clinical and laboratory data were collected to assess the safety of CCP administration. Antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were measured in the CCP products and in patients before transfusion and at various time points post-transfusion. Correlation between the administered SARS-CoV-2 administered v

SUBMITTER: Ikeda S 

PROVIDER: S-EPMC9877592 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature